Travere Therapeutics Inc (TVTX) — Technical state
As of 2026-11-02 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.
The Closelooknet read
- Closelooknet score: 43 out of 100 (momentum 62 · quality 29 · valuation 10), as of 2026-11-03.
- Signal: Pullback inside an uptrend stack — Trades -16.1% vs the 50-day and +5.4% vs the 200-day average, 28.3% below the 52-week high and +118.1% off the 52-week low. Computed from daily closes. (as of 2026-11-02)
- Trend: Travere Therapeutics Inc trades 16.1% below its 50-day and 5.4% above its 200-day moving average. (as of 2026-11-02)
Travere Therapeutics develops and sells medicines for rare kidney and metabolic disorders. Its lead product, Filspari, treats IgA nephropathy by targeting two pathways involved in the disease's progression, and Thiola treats cystinuria, a genetic disorder causing kidney stones.
The full read — the desk's view, the earnings record, peers and the company snapshot — is on the TVTX overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.
Trades -16.1% vs the 50-day and +5.4% vs the 200-day average, 28.3% below the 52-week high and +118.1% off the 52-week low. Computed from daily closes.
The moving-average stack
- vs 20-day-4.6%
- vs 50-day-16.1%
- vs 200-day+5.4%
- 52-week band28.3% off the high · +118.1% off the low
- Streak4 consecutive down sessions
- 50-day crossprice crossed down through the 50-day 29 sessions ago
- Stochastic%K 8.9 · %D 21.5 · bear cross
Continue: the TVTX chart & overview · quality & forensics · the earnings record · the signal board
FAQ · from the current data · as of 2026-11-02
Quick answers
What is the current Closelooknet signal on TVTX?
Pullback inside an uptrend stack — Trades -16.1% vs the 50-day and +5.4% vs the 200-day average, 28.3% below the 52-week high and +118.1% off the 52-week low. Computed from daily closes. As of 2026-11-02; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.
Is TVTX above its 50-day and 200-day moving averages?
As of 2026-11-02, Travere Therapeutics Inc trades -16.1% below its 50-day and +5.4% above its 200-day average, with the 20-day -4.6% away.
How far is TVTX from its 52-week high?
28.3% below the 52-week high and 118.1% above the 52-week low, as of 2026-11-02.
Mentioned on Closelooknet
Where TVTX appears in the diary — 1 piece, newest first. Every link is our own writing.
Go deeper
Dailies
- A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000
Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG…
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ARGX.BR Argen-Xindustry
- ONC BeiGene, Ltd.industry
- UCB.BR UCB SAindustry
- ARGX argenx NV ADRindustry
- REGN Regeneron Pharmaceuticals Incindustry
- KOD Kodiak Sciences Incindustry
- REPL Replimune Group Incindustry
- MRNA Moderna Incindustry
- EXEL Exelixis Incindustry
- ARQT Arcutis Biotherapeutics Incindustry
- VRDN Viridian Therapeutics Incindustry
- XNCR Xencor Incindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- BHVN Biohaven Ltd.industry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- KYMR Kymera Therapeutics Incindustry
- SEPN Septerna, Inc. Common Stockindustry
- ADMA ADMA Biologics Incindustry
- IRON Disc Medicine Inc.industry